Thursday, September 21, 2017

Aptose Looking Toward Human Studies

I've tried to go to some length to be clear that Aptose Biosciences (NASDAQ:APTO) is a very high-risk biotech stock, and the company has continued to back up that notion. Management has not been able to resolve manufacturing issues with its promising cMyc-inhibitor APTO-253 and has shifted its focus to another preclinical candidate (CG'806), but progress toward human testing has remained frustratingly slow.

Aptose has been an interesting study in all of the “i's” that have to be dotted and “t's” that have to be crossed to get a drug from the lab and into human trials (let alone through trials and FDA and onto the market). Unfortunately, investors don't buy stocks to learn things and the shares have chopped along below $2 since my last update. I normally don't bother with preclinical biotechs, and I'm not really advising anybody else to either, but I remained intrigued by the strong preclinical signals of efficacy and safety of these two drugs. The odds are that the light at the end of the tunnel is an oncoming train (that's how it goes in biotech and that's not an Aptose-specific comment), but I can still argue for a value well above today's price.

Continue here:
Aptose Looking Toward Human Studies

No comments: